-
Mashup Score: 8
Key PointsCD37 is a surface receptor present on most AML blasts, which has unique internalization properties when compared with normal blood cells.Treatmen
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 6
PURPOSEDenileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma | Journal of Clinical Oncology https://t.co/w8tFBRweag
-
-
Mashup Score: 46CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? - 7 day(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? https://t.co/AFmah0YwqW
-
-
Mashup Score: 46CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? - 8 day(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? https://t.co/AFmah0YwqW
-
-
Mashup Score: 45CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? - 10 day(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? https://t.co/AFmah0YwqW
-
-
Mashup Score: 17Frontiers | Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma - 10 day(s) ago
1 The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China 2 China-New Zealand Joint Laboratory on Biomedicine and Health, Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong- Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health,
Source: www.frontiersin.orgCategories: General Medicine News, Oncologists1Tweet-
Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma https://t.co/VPCY91SzKN
-
-
Mashup Score: 5The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma - 16 day(s) ago
Chimeric antigen receptor (CAR) T-cell therapy has changed treatment landscape of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and more older patients have been treated with c…
Source: www.tandfonline.comCategories: General Medicine News, Oncologists1Tweet-
The current understanding of chimeric antigen receptor (CAR) T-cell therapy for older patients with relapsed or refractory large B-cell lymphoma: Leukemia & Lymphoma: Vol 0, No 0 - Get Access https://t.co/WJP5AOWY7t
-
-
Mashup Score: 6
Introduction: The association of acute lymphoblastic leukaemia (ALL) and cystic fibrosis (CF) is rare. We present the case of a paediatric patient affected by C…
Source: journals.sagepub.comCategories: General Medicine News, Oncologists1Tweet-
Combined CAR-T/HSCT approach in a patient with refractory acute lymphoblastic leukemia and cystic fibrosis - https://t.co/8UQgT1oLAy
-
-
Mashup Score: 18
This review examines the incidence of second primary cancers after treatment with chimeric antigen receptor T cells in patients with hematologic cancers.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
@JAMAOnc https://t.co/5HmtLpyqBA Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
-
-
Mashup Score: 6Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia - 30 day(s) ago
Key Points. Inati-cel can induce high and durable responses in r/r B-ALL patients with best ORR achieving 85.4% and median DOR being 20.7 months.At the med
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia https://t.co/tSfeZa1Wlt
-
CD37 in acute myeloid leukemia: a novel surface target for drug delivery https://t.co/wIZxVVKJXW